KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment: 2022-2024

  • Ginkgo Bioworks Holdings' Asset Writedowns and Impairment was N/A to -$43.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $69.4 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2024, which is 96.03% down from last year.
  • Per Ginkgo Bioworks Holdings' latest filing, its Asset Writedowns and Impairment stood at -$43.0 million for Q2 2024, which was down 138.29% from $112.4 million recorded in Q3 2023.
  • In the past 5 years, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment registered a high of $112.4 million during Q3 2023, and its lowest value of -$43.0 million during Q2 2024.
  • For the 3-year period, Ginkgo Bioworks Holdings' Asset Writedowns and Impairment averaged around $17.3 million, with its median value being $0 (2022).